Mitsu Chem Plast Ltd Q2 FY2026 Concall Summary

Key Takeaways

• Volume-led growth, margin recovery underway: Revenue rose 13.63% YoY with H2 volume growth targeted at 30%, while EBITDA margin improved 53 bps QoQ to 6.37% as cost optimization efforts begin to show.
• The ₹1,000 crore ambition is a placeholder, not a plan: Management reiterated the FY28 target but declined to share specifics, saying plans are under development and will be disclosed "very soon."
• Structural margin disadvantage acknowledged: Margins are half of some peers because of Maharashtra power costs, exclusive use of prime materials for pharma/chemical clients, and smaller buying scale.
• Export and new product engines are turning: Now exporting to 17+ countries, added 25+ new products in six months, and the Furnastra healthcare brand is gaining recognition ahead of MEDICA participation.
• What to watch next quarter: Whether the promised ₹1,000 crore roadmap materializes with concrete CapEx and funding details, the pace of margin expansion toward management's 20% healthcare target, and conversion of recently added customers into repeat orders.

The ₹1,000 Crore Question

• Target restated, not substantiated: Management repeated the aspiration to reach ₹1,000 crore in annual revenue by FY28, but when pressed on feasibility given the current ~₹350 crore run-rate, offered no bridge, timeline, or funding plan.
• Plans are still internal: The company is "working on plans" and will present them to the Board before any public disclosure; no CapEx project has been declared yet.
• M&A not ruled out, not confirmed: An analyst asked whether the target is contingent on acquisitions; management did not answer directly, saying only that plans will be announced soon.

Dedhia: "We will announce very soon what are the plans and everything because yet we haven't declared anything yet. So, let us wait for sometimes."

Margin Structure & Competitive Position

• The half-the-peer gap: Management acknowledged container segment margins are well below the 12-13% peers achieve, attributing the gap to three structural factors: higher power costs in Maharashtra versus Daman, Silvassa or Gujarat; exclusive use of prime-grade materials because the customer base is chemical and pharmaceutical companies with strict norms; and smaller procurement volumes that weaken buying power versus larger purchasers.
• Recovery is incremental, not step-change: EBITDA margin improved 53 bps QoQ to 6.37% and 21 bps in H1 to 6.13%, driven by cost optimization and operating efficiency rather than any structural reset.
• The COVID margin hangover: Margins halved from ~13% in FY21; management characterized that period as anomalous and said there is "no specific reason" for the decline beyond normalization, while noting efforts to recover are ongoing.

Dedhia: "And being in Maharashtra, we have always some disadvantage that the power factor also a little higher than the other competitors because most of the competitors are either in Daman, Silvassa or Gujarat."

Dedhia: "as a company, we have to be very safer side because we are supplying to too many chemical and pharmaceutical company. So, we have to adhere to some of the norms also. So, we restricted to use only prime materials. So, these are also one of the reasons."

Segment Dynamics

• Customer base is granular: No single customer exceeds 2-3% or 5% of revenue, with diversification across chemical, pharma, FMCG, and hospital furniture segments mitigating concentration risk.
• Lead conversion is slow: Technical products take around one year from lead to business because new shapes and designs must be developed and approved.

Export & Product Development

• Geographic reach expanding: Now exporting to 17+ countries; participation in Arab Health (Dubai), MEDICA (Germany, upcoming November), WXH (Miami), ArabPlast (US/Latin America), and ChemTECH Expo (Mumbai) is building international visibility.
• Repeat order pipeline building: Products have been approved by companies in the 17 countries, with some still under approval; management expects "many more repeat orders" from those markets.
• New product velocity: Added 25+ new products in the last six months, with more additions planned in the coming year.
• PCR product leadership: Mitsu claims to be the first company offering post-consumer recycled products across the full range (100 ml to 250 litre) for about 1.5 years; PCR is not permitted in food and pharma but chemical companies have started adopting it, and the company is doing value engineering to increase PCR usage.

Dedhia: "I think Mitsu was the first company who was giving PCR product since I think 1.5 year that we are ready with all our PCR facility from 100 ml to 250 litre."

Capacity & Raw Material

• Capacity expansion underway: Two new machines added in the last week, with more installations in progress; the expansion did not impact the reported quarter but positions for the next growth wave.
• Headroom exists: More capacity remains unutilized; management is trying to utilize it alongside new additions.
• Raw material stability with caveats: HDPE prices were stable last quarter and currently, though some volatility exists from import material and traders selling at lower cost; the company buys from petrochemical plants and has MoUs with some suppliers for preference.
• Pricing is formula-driven: Most customers are on monthly pricing, some on quarterly; prices change monthly on a formula basis, providing some pass-through protection.
• Export hedging is minimal: Export volume is low; hedging is done only for confirmed amounts, and most amounts are received in advance.

Guidance & Commitments

Key Metrics